A 38-year-old man with schizophrenia has been on haloperidol 10 mg/day for 6 months. He now presents with involuntary orofacial movements, tongue protrusion, and lip smacking that persist even when he is asleep. His psychiatrist is concerned about medication-induced movement disorder. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis **Key Point:** The patient exhibits **tardive dyskinesia (TD)** — involuntary orofacial movements (tongue protrusion, lip smacking) that persist during sleep, indicating a late-onset, potentially irreversible antipsychotic side effect. ## Why Switch Antipsychotics? **High-Yield:** Once TD develops on a typical antipsychotic (haloperidol), the standard of care is to: 1. **Switch to a second-generation antipsychotic (SGA)** — SGAs have lower risk of TD and may allow partial or complete resolution of existing TD. 2. **Gradual discontinuation** of the offending agent — abrupt cessation can worsen dyskinesia transiently. 3. **Risperidone, olanzapine, quetiapine, or aripiprazole** are preferred choices; clozapine is reserved for treatment-resistant cases. **Clinical Pearl:** Benztropine (anticholinergic) does NOT reverse TD; it may even worsen it. Anticholinergics are used for acute dystonia and akathisia, not tardive dyskinesia. ## Management Algorithm ```mermaid flowchart TD A[Patient on typical antipsychotic develops TD]:::outcome B{Confirm TD diagnosis}:::decision B -->|Yes| C[Switch to SGA]:::action B -->|No| D[Reassess diagnosis] C --> E[Taper original agent over 2-4 weeks]:::action E --> F[Monitor for TD improvement]:::action F --> G{TD resolves?}:::decision G -->|Partial/Complete| H[Continue SGA]:::outcome G -->|Persistent| I[Consider valbenazine or deutetrabenazine]:::action ``` **Mnemonic: SWITCH for TD** = **S**witch to SGA, **W**ean off typical, **I**nvestigate reversibility, **T**rial of vesicular monoamine transporter inhibitors if refractory, **C**ontinue monitoring, **H**old anticholinergics. ## Why Not the Other Options? - **Benztropine + continue haloperidol:** Anticholinergics worsen or unmask TD; continuing the causative agent perpetuates the disorder. - **Immediate clozapine switch:** While clozapine is highly effective for TD, it is not first-line for de novo TD management; reserved for treatment-resistant psychosis or severe, refractory TD. - **Dose reduction + propranolol:** Haloperidol dose reduction alone is insufficient; propranolol may help akathisia but not TD. [cite:KD Tripathi 8e Ch 12]